ASP4058 (p.o., daily for 21 days) reduces the clinical score in a dose-dependent manner and the cumulative clinical score from day 0 to 21 dpi at 0.03, 0.1 and 0.3 mg/kg are 15.5±1.48, 9.50±2.17 and 1.17±1.17, respectively, while that of vehicle-treated group is 15.5±0.619 in rats. ASP4058 prevents decreases in body weight of EAE rats[1].
ASP4058 (p.o., daily for day 12 to day 45) maintains the clinical score at a relatively low level and the cumulative clinical scores (18-45 dpi) among the groups treated with 0.1 and 0.3 mg/kg dosages are 6.90±2.85 and 5.60±2.21, respectively in mice. The ED50 values for ASP4058 is 0.063 mg/kg[1].
| Animal Model: | Male Lewis rats with an induction of EAE[1]. |
| Dosage: | 0.03, 0.1 or 0.3 mg/kg. |
| Administration: | Oral administration once daily for 21 days. |
| Result: | Reduced the clinical score in a dose-dependent manner and the cumulative clinical score. |
| Animal Model: | SJL mice immunized with PLP139-151 and boosted with pertussis toxin developed relapsing-remitting EAE[1]. |
| Dosage: | 0.1 and 0.3 mg/kg |
| Administration: | Oral administration once daily from day 12 to day 45. |
| Result: | Maintained the clinical score at a relatively low level and the cumulative clinical scores (18-45 dpi). |
